The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series

Koné‐Paut, Isabelle; Cimaz, Rolando; Herberg, Jethro; Bates, Oliver; Carbasse, Aurélia; Saulnier, Jean Pierre; Maggio, Maria Cristina; Antón, Jordi; Piram, Maryam

doi:10.1016/j.autrev.2018.01.024

Cited by 99 publications

(72 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings demonstrate that Candida PAMPs initiate arteritis by activating TRMs in the aortic root and inducing chemokine and cytokine production in a mouse model of vasculitis resembling KD. Several case reports have shown promising results using the IL-1R antagonist Anakinra to treat KD (57,58) and new therapeutics that target the CCL2/CCR2 chemokine axis are currently in clinical trials for cancer (59,60). Finally, Syk inhibitors are available and have been in clinical trials for the treatment of rheumatoid arthritis (61).…”

Section: Discussionmentioning

confidence: 99%

Dectin-2–induced CCL2 production in tissue-resident macrophages ignites cardiac arteritis

Miyabe¹,

Miyabe²,

Moreno³

et al. 2019

Journal of Clinical Investigation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Dectin-2–induced CCL2 production in tissue-resident macrophages ignites cardiac arteritis

Miyabe¹,

Miyabe²,

Moreno³

et al. 2019

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…In highly refractory cases, plasma exchange, cytotoxic agents, or other biologicals have been used [28]. There are a few recent reports of successful use of the IL-1 receptor antagonist, anakinra, for the treatment of highly refractory KD [64].…”

Section: Treatment Options For Resistant Kdmentioning

confidence: 99%

Kawasaki Disease

Pilania¹,

Singh²

2019

Periodic and Non-Periodic Fevers

View full text Add to dashboard Cite

Kawasaki disease (KD) is an acute and usually self-limiting medium vessel vasculitis of childhood that has a predilection to involve the coronary arteries. It is characterized by the sequential appearance of a constellation of clinical features [1]. However, none of these clinical findings is, in itself, pathognomonic of KD. Many of these clinical features can, in fact, be seen in other common febrile illnesses of children. It is for this reason that the diagnosis of KD is often considered to be a clinical challenge [2]. Approximately 15-25% of untreated patients may go on develop coronary artery abnormalities (CAAs) and this remains the major cause of morbidity, and occasional mortality, in KD [3].

show abstract

“…Anakinra treatment in this case was 10 weeks [12]. In contrast to these cases, however a retrospective case series published in January 2018 analyzed multiple cases and found that anakinra showed "neither a striking nor a rapid decrease of coronary dilations" and could not determine if anakinra itself had effects on the CAA [13].…”

Section: Discussionmentioning

confidence: 72%

Complete Regression of Giant Aneurysms in an Infant with Delayed Diagnosis and Refractory Kawasaki Disease via Combination Anticytokine Therapy: Case Report and Review of Similar Cases

Williams

Nagaraju

Gorelik

2020

Case Reports in Rheumatology

View full text Add to dashboard Cite

Background. Kawasaki disease (KD) is an inflammatory vasculitis and is the most common cause of acquired childhood heart disease in developed countries. Current treatment with intravenous immunoglobulin (IVIG) is often ineffective in patients with delayed or refractory disease. We present a case of combination anticytokine therapy in an infant with delayed and refractory KD. Case Presentation. A 3-month-old infant presented with refractory KD with giant aneurysms after a delayed diagnosis of one month. Use of combination anticytokine therapy led to resolution of giant aneurysms over approximately 6 months. Conclusions. Our case is unique in effective use of anticytokine therapy in very delayed disease with giant aneurysms. Additionally, we review other cases for a broader perspective. Prospective study of anticytokine therapy for patients with giant aneurysms may be warranted.

show abstract

The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series

Cited by 99 publications

References 26 publications

Dectin-2–induced CCL2 production in tissue-resident macrophages ignites cardiac arteritis

Dectin-2–induced CCL2 production in tissue-resident macrophages ignites cardiac arteritis

Kawasaki Disease

Complete Regression of Giant Aneurysms in an Infant with Delayed Diagnosis and Refractory Kawasaki Disease via Combination Anticytokine Therapy: Case Report and Review of Similar Cases

Contact Info

Product

Resources

About